These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36369075)

  • 1. Community pharmacist-provided opioid intervention frequencies and barriers.
    Nichols MA; Kepley KL; Rosko KS; Hudmon KS; Curran GM; Ott CA; Snyder ME; Miller ML
    J Am Pharm Assoc (2003); 2023; 63(1):336-342. PubMed ID: 36369075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid Use Disorder Curricular Content in US-Based Doctor of Pharmacy Programs.
    Nichols MA; Riley EG; Chao AS; Sales CG; Miller ML; Curran GM; Ott CA; Snyder ME; Hudmon KS
    Am J Pharm Educ; 2023 Jun; 87(6):100061. PubMed ID: 37316134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.
    Rao D; Ford JH; Shiyanbola OO
    Addict Sci Clin Pract; 2024 Apr; 19(1):27. PubMed ID: 38589965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of academic detailing for pharmacists on opioid use disorder and harm reduction.
    DiPaula BA; Cooke CE; Boyle CJ; Love RC
    J Am Pharm Assoc (2003); 2022; 62(1):241-246. PubMed ID: 34690080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
    Wu LT; Mannelli P; John WS; Anderson A; Schwartz RP
    Subst Abuse Treat Prev Policy; 2023 Sep; 18(1):55. PubMed ID: 37697326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
    Tutag Lehr V; Nolan C
    J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "The gatekeepers in prevention": Community pharmacist perceptions of their role in the opioid epidemic.
    Vadiei N; Eldridge LA; Meyerson BE; Agley J
    Subst Abus; 2022; 43(1):319-327. PubMed ID: 34214407
    [No Abstract]   [Full Text] [Related]  

  • 9. What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.
    Nielsen S; Sanfilippo P; Picco L; Bruno R; Kowalski M; Wood P; Larney S
    Int J Clin Pharm; 2021 Apr; 43(2):420-429. PubMed ID: 32533428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacists' perspectives on MedSMA℞T: A serious game to educate youth about opioid safety.
    Abraham O; Slonac E; Paulsen Z
    J Am Pharm Assoc (2003); 2023; 63(4):1087-1094.e1. PubMed ID: 37116795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of the characteristics of pharmacist-based immunization services in North Carolina: results of a pharmacist survey.
    Kummer GL; Foushee LL
    J Am Pharm Assoc (2003); 2008; 48(6):744-51. PubMed ID: 19019803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community pharmacists' attitudes toward providing care and services to patients with severe and persistent mental illness.
    Watkins A; McKee J; Hughes C; Pfeiffenberger T
    J Am Pharm Assoc (2003); 2017; 57(3S):S217-S224.e2. PubMed ID: 28408170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of community pharmacy-based services for type-2 diabetes in an Indonesian setting: pharmacist survey.
    Wibowo Y; Parsons R; Sunderland B; Hughes J
    Int J Clin Pharm; 2015 Oct; 37(5):873-82. PubMed ID: 25986291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community pharmacists' perceptions, attitudes and barriers towards pharmacist-led minor ailment services in Malaysia.
    Selvaraj A; Redzuan AM; Hatah E
    Int J Clin Pharm; 2020 Apr; 42(2):777-785. PubMed ID: 32006142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Readiness of community pharmacies to implement an opioid safety intervention.
    Floyd AS; Silcox J; Cousin E; Irwin AN; Gray M; Bolivar D; Bratberg J; Arnold J; Al-Jammali Z; Hansen RN; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(1):275-283.e1. PubMed ID: 36496310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community pharmacists' opinions and practice of pharmaceutical care at chain pharmacy and independent pharmacy in China.
    Xi X; Huang Y; Lu Q; Ung COL; Hu H
    Int J Clin Pharm; 2019 Apr; 41(2):478-487. PubMed ID: 30864081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacist views and pharmacy capacity to deliver professional services in the United Arab Emirates.
    Alzubaidi H; Saidawi W; Mc Namara K
    Int J Clin Pharm; 2018 Oct; 40(5):1106-1115. PubMed ID: 29926256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.